GET DAILY SIGNALSWhy Is Puma Biotechnology (PBYI) Stock Down -19.75% Today?
Key Takeaways
- PBYI shares plunged roughly 19.75% to $7.84, extending a selloff that began after third-quarter results were released.
- The primary catalyst was a revenue miss and a softer-than-expected U.S. demand picture for its lead drug NERLYNX.
- Secondary pressures included a $2.1 million royalty reversal tied to generic NERLYNX competition in China and a lowered top end of full-year revenue guidance.
- The decline unfolded against a broader risk-off tone in biotech as elevated Treasury yields and a pending Fed decision weighed on the sector.
- Traders are now watching fourth-quarter execution, prescription trends, and the company's alisertib pipeline updates.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages for deeper analysis.
- Interested in automated strategies? Explore Trending AI Robots to see top-performing trading bots under current market conditions.
Opening Summary
Puma Biotechnology, Inc. (PBYI), a Los Angeles-based biopharmaceutical company focused on cancer care, saw its shares tumble on Thursday, falling roughly 19.75% to $7.84 from a prior closing price of $9.77. The company commercializes NERLYNX (neratinib) for HER2-positive breast cancer and is advancing alisertib, an Aurora kinase A inhibitor, through mid-stage clinical trials. The sharp decline reflects a negative market reaction to third-quarter financial results reported after Wednesday's close, with investors focusing on a revenue shortfall and signs of weakening U.S. demand for the company's flagship therapy.
Earnings Results Miss on Revenue
The headline driver of the move was PBYI's third-quarter report. Total revenue of $55.1 million came in below consensus estimates near $57.5 million, a top-line miss that overshadowed a bottom-line beat. Non-GAAP earnings per share of $0.15 exceeded expectations of roughly $0.09, and the company raised its full-year net income guidance to $20 million to $22 million from a prior $17 million to $20 million. However, the earnings improvement was driven in part by lower-than-expected spending and a cleaner balance sheet rather than stronger commercial momentum, leaving investors unconvinced.
Weak NERLYNX Demand and China Royalty Pressure
Beneath the headline numbers, the commercial story deteriorated. While reported NERLYNX net product revenue of $54.1 million edged up from $53.6 million in the second quarter, that figure was flattered by $3.6 million of ex-U.S. supply revenue. U.S. net NERLYNX sales actually fell to $50.6 million from $53.6 million sequentially. Demand metrics reversed after a strong prior quarter: new prescriptions dropped 13%, patient enrollments fell 12%, and total prescriptions slipped 5%. Management attributed part of the softness to sales territory vacancies, which it expects to normalize.
Royalty revenue compounded the pressure, collapsing to about $1.0 million from $2.6 million in the prior quarter. The decline included a $2.1 million cumulative reversal after generic versions of NERLYNX in China crossed a contractual market-share threshold, triggering a permanently lower royalty rate on future China sales. The company also narrowed its full-year total revenue guidance to $224 million to $227 million from $224 million to $231 million, trimming the top end, while cutting royalty guidance to $18 million to $19 million.
Market Context and Trading Activity
The selloff in PBYI unfolded amid a broader risk-off tone across healthcare and biotech, as surging Treasury yields above 5% and a pending Federal Reserve rate decision pressured risk assets. Peers in the oncology and biotech space traded lower in sympathy, suggesting macro factors amplified company-specific disappointment. Trading activity was elevated relative to the stock's typical daily volume, consistent with an earnings-driven repricing. The move pushed shares decisively through recent support levels and well below the prior session's range, signaling a technical breakdown as the stock extended losses after an earlier 8.6% decline in the previous session.
What Comes Next for PBYI
Looking ahead, investors will focus on whether PBYI can stabilize NERLYNX prescription and enrollment trends in the fourth quarter, particularly as management guided to a back-end-weighted quarter with $67 million to $70 million in total revenue and $10 million to $12 million in net income. Gross-to-net deductions, which have been creeping higher on Medicaid and 340B mix, remain a key watch item. The company's alisertib Phase 2 programs in small cell lung cancer and breast cancer represent the primary pipeline catalysts, though data readouts carry execution risk. Broader macro conditions, including interest rates and sector sentiment, will also influence near-term trading. As with any biotech, risks include commercial execution, competitive pressure from generics, and the inherent uncertainty of clinical development.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of automated bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of approaches to explore. If you are looking for data-driven ways to navigate volatile markets, consider browsing the Trending AI Robots to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PBYI's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for PBYI moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 instances where the indicator moved out of the overbought zone. In 37 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a move down at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBYI as a result. In 76 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for PBYI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
PBYI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 261 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
PBYI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 210 of 231 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.640) is normal, around the industry mean (2.788). P/E Ratio (18.434) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer
Industry Biotechnology
Advertisement